医学
脊柱(分子生物学)
结果(博弈论)
疾病
协商一致会议
德尔菲法
梅德林
外科
内科学
生物信息学
人工智能
政治学
数理经济学
法学
生物
计算机科学
数学
作者
Rafael De la Garza Ramos,C. Rory Goodwin,Vithushan Surendran,Markian Pahuta,Shalin S. Patel,Mark A. MacLean,Arjun Sahgal,Laurence D. Rhines,Danielle Golub,Cordula Netzer,Nicolas Dea,Jorrit‐Jan Verlaan,Alessandro Gasbarrini,Jeremy Reynolds,Ori Barzilai,Chetan Bettegowda,Stefano Boriani,Ángel Arévalo-Martı́n,Ziya L. Gokaslan,Áron Lazáry
出处
期刊:Spine
[Lippincott Williams & Wilkins]
日期:2025-08-25
卷期号:50 (24): 1683-1691
标识
DOI:10.1097/brs.0000000000005479
摘要
Study Design. Delphi consensus. Objective. To define an optimal surgical composite outcome measure in patients with metastatic spine disease (OSCO-M) through international consensus among key opinion leaders. Materials and Methods. Members of the AO Spine Knowledge Forum Tumor, an international group of dedicated spine oncology surgeons and oncologists, participated in a modified Delphi process between March 2023 and November 2024. The study was conducted in 2 parts. The first part aimed on identifying which outcome variables were deemed important to be included in the composite outcome. The second part focused on the definition of a successful outcome with regards to the agreed variables from Part 1. Each part consisted of a questionnaire and a consensus meeting. Consensus was achieved when a threshold of 70% agreement was reached. Results. A total of 42 dedicated spine oncology surgeons and oncologists from North America, Latin America, Europe, and Asia participated. Over 87% of respondents agreed that composite measures reflect the multidimensional aspect of the surgical process more than an individual outcome variable. Most respondents (93%) agreed/strongly agreed that composite measures should be used to assess the quality of surgical care in spine oncology. Through consensus, the following three outcome variables were selected to define the OSCO-M: the absence of SAVES-V2 (Spinal Adverse Events Severity System, Version 2) grade 3 adverse events or higher within 30 days of surgery, maintaining or improving ECOG (Eastern Cooperative Oncology Group) performance status at 90 days, and being ambulatory (with or without aid) at 90 days. Conclusion. This is the first study defining a composite outcome measure in oncologic surgery for spinal metastases derived from an international group of key opinion leaders in spine oncology. The OSCO-M may be useful for future research in spine tumor patients and serve as a benchmark to optimize outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI